These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 24500308)

  • 1. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
    Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
    Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
    J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients.
    Zawierucha J; Małyszko J; Małyszko JS; Prystacki T; Marcinkowski W; Dryl-Rydzyńska T
    Pol Arch Intern Med; 2017 Dec; 127(12):840-845. PubMed ID: 29067991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
    Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].
    Zawierucha J; Małyszko J; Małyszko J; Dryl-Rydzyńska T; Prystacki T; Marcinkowski W
    Przegl Lek; 2016; 73(4):229-32. PubMed ID: 27526425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
    Koc H; Hoser H; Akdag Y; Kendir C; Ersoy FF
    Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
    Zwiech R; Dryja P; Łacina D; Nykiel P; Sek-Szczepanowska K; Bratkowska K; Pietrzak B; Chrul S
    Wiad Lek; 2011; 64(4):267-73. PubMed ID: 22533150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Staniforth ME; Cheng SC; Coyne DW
    Clin Nephrol; 2005 Jun; 63(6):454-60. PubMed ID: 15960147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.